Jansen JH - Search Results

1

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T. Lohse S, et al. Among authors: jansen jh. Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3. Cancer Res. 2016. PMID: 26634925

2

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, Leusen JH. de Haij S, et al. Among authors: jansen jh. Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-4109. Epub 2010 Mar 30. Cancer Res. 2010. PMID: 20354182

3

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH. Boross P, et al. Among authors: jansen jh. Haematologica. 2011 Dec;96(12):1822-30. doi: 10.3324/haematol.2011.047159. Epub 2011 Aug 31. Haematologica. 2011. PMID: 21880632 Free PMC article.

4

Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.

Boross P, Jansen JH, Pastula A, van der Poel CE, Leusen JH. Boross P, et al. Among authors: jansen jh. Immunol Lett. 2012 Mar 30;143(1):44-52. doi: 10.1016/j.imlet.2012.01.004. Epub 2012 Jan 23. Immunol Lett. 2012. PMID: 22285696

5

Inhibition of the classical and lectin pathway of the complement system by recombinant LAIR-2.

Olde Nordkamp MJ, Boross P, Yildiz C, Jansen JH, Leusen JH, Wouters D, Urbanus RT, Hack CE, Meyaard L. Olde Nordkamp MJ, et al. Among authors: jansen jh. J Innate Immun. 2014;6(3):284-92. doi: 10.1159/000354976. Epub 2013 Nov 1. J Innate Immun. 2014. PMID: 24192271 Free PMC article.

6

Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.

Boross P, Jansen JH, van Tetering G, Nederend M, Brandsma A, Meyer S, Torfs E, van den Ham HJ, Meulenbroek L, de Haij S, Leusen JH. Boross P, et al. Among authors: jansen jh. Immunol Lett. 2014 Aug;160(2):151-7. doi: 10.1016/j.imlet.2014.02.005. Epub 2014 Mar 5. Immunol Lett. 2014. PMID: 24613852

7

FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells.

Boross P, van Montfoort N, Stapels DA, van der Poel CE, Bertens C, Meeldijk J, Jansen JH, Verbeek JS, Ossendorp F, Wubbolts R, Leusen JH. Boross P, et al. Among authors: jansen jh. J Immunol. 2014 Dec 1;193(11):5506-14. doi: 10.4049/jimmunol.1302012. Epub 2014 Oct 29. J Immunol. 2014. PMID: 25355925

8

Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.

Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P. Brandsma AM, et al. Among authors: jansen jh. Cancer Immunol Res. 2015 Dec;3(12):1316-24. doi: 10.1158/2326-6066.CIR-15-0099-T. Epub 2015 Sep 25. Cancer Immunol Res. 2015. PMID: 26407589

9

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.

Meyer S, Nederend M, Jansen JH, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R, Boross P, Rouwendal G, Leusen JH. Meyer S, et al. Among authors: jansen jh. MAbs. 2016;8(1):87-98. doi: 10.1080/19420862.2015.1106658. Epub 2015 Oct 14. MAbs. 2016. PMID: 26466856 Free PMC article.

10

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P. Overdijk MB, et al. Among authors: jansen jh. J Immunol. 2016 Aug 1;197(3):807-13. doi: 10.4049/jimmunol.1501351. Epub 2016 Jun 17. J Immunol. 2016. PMID: 27316683

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

314 results

Search Page

Filters